Ledger.Open graph →
SEC Form D · filed February 4, 2021

Exacis Biotherapeutics Inc

Offering
$3.0M
Sold
$50K
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (9)

Scott Radke · New York, NYExecMark Corrigan · Cambridge, MADirectorMatthew Angel · Cambridge, MADirectorRegan Bozman · San Francisco, CAExecGregory Fiore · Cambridge, MAExecMike Jacobellis · New York, NYDirectorAndrew A. Tisdale · Providence, RIDirectorPhilippe Schulligen · Duluth, GADirectorLattice Capital II GP LLC · San Francisco, CADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗